Overview

Corporate Presentation

Corporate Presentation - March 2023

Download Presentation

Email Alerts

Register to receive real time alerts

Sign Up

IR Contacts

Get in touch with our IR team

Contact Us

Latest Press Releases
Mar 16, 2023
Trevi Therapeutics Announces Fourth Quarter and Year End 2022 Financial Results and Provides Business Update

Multiple trial initiations planned for 2023 to progress Haduvio in chronic cough indications Management to host a conference call and webcast today at 4:30 p.m. EDT NEW HAVEN, Conn., March 16,...

Mar 9, 2023
Trevi Therapeutics to Report Q4 and Year End 2022 Financial Results and Provide a Corporate Update on March 16, 2023

Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in...

Mar 8, 2023
Trevi Therapeutics Announces Notice of Allowance for U.S. Patent Application Covering Use of Haduvio™ (nalbuphine ER) for the Treatment of Chronic Cough in Idiopathic Pulmonary Fibrosis

Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in...

View All Press Releases

Events
BIO-Europe Spring
Monday, March 20, 2023 - Thursday, March 30, 2023

Dates: March 20-22, 2023 (in-person) and March 28-30, 2023 (virtual)

Add to Calendar

View All Events

We are developing the investigational therapy Haduvio™ (nalbuphine ER) to treat serious neurologically mediated conditions by targeting the central and peripheral nervous systems.

Our novel oral formulation has the potential to unlock new market opportunities and significantly improve the quality of life of patients who currently have few treatment options.

Explore Our Pipeline